#1 Clinical Trials Search in Europe

Cladribine

Cladribine is a medication being studied in clinical trials for several conditions, including multiple sclerosis, leukemia, and lymphoma. These trials aim to evaluate cladribine’s safety, effectiveness, and optimal dosing in different patient populations. By examining cladribine in controlled research settings, scientists hope to better understand its therapeutic potential and expand treatment options for patients.

Table of Contents

What is Cladribine?

Cladribine is a medication used in the treatment of various blood cancers and multiple sclerosis. It’s also known by several other names, including:

  • 2-CdA
  • 2-chlorodeoxyadenosine
  • Leustatin
  • Mavenclad (for the tablet form used in multiple sclerosis)
This drug belongs to a class of medications called purine nucleoside analogues[1]. These drugs work by interfering with the DNA of cancer cells or overactive immune cells, ultimately leading to their death.

What Conditions Does Cladribine Treat?

Cladribine is used to treat several conditions:

  • Acute Myeloid Leukemia (AML): A type of blood cancer that affects the bone marrow[2]
  • Hairy Cell Leukemia: A rare form of blood cancer[3]
  • Multiple Sclerosis (MS): An autoimmune disease affecting the central nervous system[4]
  • Mantle Cell Lymphoma: A type of non-Hodgkin lymphoma[5]
  • Myelodysplastic Syndromes: A group of disorders where blood cells don’t mature properly in the bone marrow[6]
It’s important to note that cladribine may be used for both newly diagnosed patients and those whose disease has returned or not responded to previous treatments (relapsed/refractory cases).

How Does Cladribine Work?

Cladribine works by interfering with the DNA of certain cells in the body:

  • In blood cancers, it targets and kills cancer cells
  • In multiple sclerosis, it reduces the number of certain immune cells (T and B lymphocytes) that are involved in the disease process[7]
By doing this, cladribine helps to slow down or stop the progression of these diseases.

How is Cladribine Administered?

Cladribine can be given in several ways, depending on the condition being treated:

  • Intravenous (IV) infusion: Given directly into a vein, often over a period of 2 hours[6]
  • Subcutaneous injection: Injected under the skin[8]
  • Oral tablets: Taken by mouth, primarily for multiple sclerosis[9]
The dosage and duration of treatment can vary widely depending on the specific condition and individual patient factors. For example, in multiple sclerosis, cladribine tablets are typically given in two treatment courses over two years[4].

Effectiveness of Cladribine

The effectiveness of cladribine varies depending on the condition being treated:

  • In acute myeloid leukemia, when combined with other drugs, cladribine has shown promising results in achieving complete remission (disappearance of all signs of cancer)[2]
  • For hairy cell leukemia, cladribine is considered highly effective, often leading to long-lasting remissions[3]
  • In multiple sclerosis, cladribine has been shown to reduce relapse rates and slow disability progression[9]
It’s important to note that response to treatment can vary from person to person, and your doctor will monitor your progress closely.

Side Effects and Safety

Like all medications, cladribine can cause side effects. Some of the most common include:

  • Lowered blood cell counts, which can increase the risk of infections and bleeding
  • Fatigue
  • Nausea
  • Skin rash
More serious side effects can include severe infections and an increased risk of certain cancers. Your healthcare team will monitor you closely for these effects[4]. It’s crucial to discuss all potential risks and benefits with your doctor before starting treatment with cladribine.

Ongoing Research and Future Prospects

Research on cladribine is ongoing, with several clinical trials exploring its use in various conditions:

  • Combining cladribine with other treatments for better outcomes in leukemia[2]
  • Using cladribine as part of conditioning regimens before stem cell transplants[10]
  • Exploring the long-term effects and optimal dosing of cladribine in multiple sclerosis[9]
These ongoing studies aim to improve our understanding of how best to use cladribine and potentially expand its applications in treating various diseases.

Aspect Details
Conditions Studied Multiple sclerosis, leukemia (hairy cell, acute myeloid), lymphoma, myelodysplastic syndromes
Administration Methods Oral tablets, subcutaneous injections, intravenous infusions
Key Outcome Measures Safety, efficacy, relapse rates, disease progression, blood cell counts, quality of life
Trial Durations Vary from months to 10+ years for long-term follow-up
Common Side Effects Lowered white blood cell counts, infections, liver toxicity
Combination Therapies Some trials combine cladribine with other drugs like rituximab or cyclophosphamide

FAQ

  • What conditions is cladribine being studied for in clinical trials? Cladribine is being investigated for multiple sclerosis, various types of leukemia including hairy cell leukemia and acute myeloid leukemia, lymphomas, and myelodysplastic syndromes.
  • How is cladribine typically administered in these trials? Administration methods vary by trial, but include oral tablets, subcutaneous injections, and intravenous infusions. Some trials use cladribine alone while others combine it with other medications.
  • What are some of the main outcomes being measured in cladribine trials? Key outcomes include safety/adverse events, effectiveness in reducing relapses or disease progression, changes in blood cell counts, quality of life measures, and long-term survival rates.
  • How long do cladribine clinical trials typically last? Trial durations vary widely, from short-term studies of a few months to long-term follow-up periods of 2-10 years to assess long-term efficacy and safety.
  • Are there any notable side effects of cladribine being monitored in trials? Common side effects being monitored include lowered white blood cell counts, infections, liver toxicity, and potential long-term effects on the immune system. Trials closely track all adverse events.

Ongoing Clinical Trials on Cladribine

  • Study of oral cladribine compared to placebo for patients with generalized myasthenia gravis

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia France Germany Greece +6

  • Study comparing standard and reduced intensity treatment in patients with acute myeloid leukemia or chronic lymphocytic leukemia who have no detectable disease after initial therapy

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Poland

  • Study of Vemurafenib and Rituximab for Untreated Hairy Cell Leukemia Patients

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on the Effectiveness of Gilteritinib and Drug Combination for Patients with Relapsed or Refractory Acute Myeloid Leukemia

    Recruiting

    1 1 1 1
    Investigated drugs:
    Czechia Germany Italy Lithuania Portugal Romania +1

  • Study on Personalized Treatment for Acute Myeloid Leukemia Using Cladribine, Daunorubicin, Cytarabine, and Drug Combinations for Specific Patient Groups

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

  • Study of rituximab followed by cladribine for patients with relapsing-remitting multiple sclerosis with less than 10 years disease duration

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

  • Effect of cladribine tablets on immune synapse in patients with relapsing multiple sclerosis

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Greece

  • Study on Cladribine for Treating Secondary Progressive Multiple Sclerosis in Patients with Recent Progression and No Recent Relapses

    Not recruiting

    1 1
    Investigated drugs:
    Poland

  • Study on the Effects of Cladribine on Brain Cells in Patients with Multiple Sclerosis

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland

  • Study of Total Body Irradiation and Cladribine Treatment Before Stem Cell Transplant in Adult Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes

    Not recruiting

    1 1 1
    Investigated drugs:
    Poland

Glossary

  • Annualized Relapse Rate (ARR): The average number of relapses a patient experiences per year, used to measure disease activity in multiple sclerosis.
  • Bioequivalence: When two medications have the same active ingredient and produce the same effect in the body, despite potentially different formulations.
  • Complete Remission (CR): The disappearance of all signs of cancer in response to treatment.
  • Expanded Disability Status Scale (EDSS): A method of measuring disability in multiple sclerosis, ranging from 0 (normal) to 10 (death due to MS).
  • Hairy Cell Leukemia (HCL): A rare, slow-growing blood cancer where the bone marrow makes too many B cells (lymphocytes).
  • Lymphoma: A type of blood cancer that affects the lymphatic system, part of the body's germ-fighting network.
  • Myelodysplastic Syndromes (MDS): A group of disorders caused by poorly formed or dysfunctional blood cells.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Relapsing-Remitting Multiple Sclerosis (RRMS): The most common form of MS, characterized by clearly defined attacks of new or increasing neurologic symptoms.
  • Secondary Progressive Multiple Sclerosis (SPMS): A phase of MS that follows relapsing-remitting MS, where disability steadily increases with or without relapses.

References

  1. https://clinicaltrials.gov/study/NCT00126321
  2. https://clinicaltrials.gov/study/NCT03181815
  3. https://clinicaltrials.gov/study/NCT02157181
  4. https://clinicaltrials.gov/study/NCT00641537
  5. https://clinicaltrials.gov/study/NCT00002879
  6. https://clinicaltrials.gov/study/NCT06021600
  7. https://clinicaltrials.gov/study/NCT04178005
  8. https://clinicaltrials.gov/study/NCT00667329
  9. https://clinicaltrials.gov/study/NCT04934800
  10. https://clinicaltrials.eu/trial/study-on-tolerance-and-effectiveness-of-total-body-irradiation-and-cladribine-for-patients-with-acute-myeloid-leukemia-and-myelodysplastic-syndromes/